Literature DB >> 26608408

Factors associated with polypharmacy and the prescription of multiple medications among persons living with HIV (PLWH) compared to non-PLWH.

Heather N Moore1, Lu Mao2, Christine U Oramasionwu1.   

Abstract

Persons living with HIV (PLWH) may be at increased risk for polypharmacy (≥5 concomitant medications) over non-PLWH, presumably due to antiretroviral therapy (ARV). Potential concerns associated with polypharmacy include clinically significant drug-drug interactions, adverse drug reactions, increased pill burden, and rising treatment-related costs. Our objective was to evaluate prescription of multiple non-ARV medications to PLWH, compared to non-PLWH, in US outpatient clinics and to identify factors associated with polypharmacy. Cross-sectional data from the 2006-2010 National Hospital Ambulatory Medical Care Survey were used for this study. Visits for PLWH were identified using HIV ICD9-CM codes 042, V08, and 079.53. Patients < 18 years of age were excluded. Relevant demographics included sex, age, race/ethnicity, and insurance status, while comorbid conditions included hypertension, diabetes, and hyperlipidemia. Multivariate logistic regression analyses evaluated factors independently associated with prescription of ≥ 5 medications. In total, 7,360,000 weighted visits for PLWH (13% aged 18-29 y; 55% aged 30-49 y; 32% aged ≥ 50 y) and 374,626,000 weighted visits for non-PLWH (18% aged 18-29 y; 32% aged 30-49 y; 50% aged ≥ 50 y) met study criteria. The greatest prevalence of hypertension, diabetes, and hyperlipidemia was in those ≥ 50 years of age (p < .001 for all comorbidities in PLWH and non-PLWH). In 2006, 16% of PLWH were prescribed ≥ 5 medications, doubling to 35% in 2010. In 2006, 24% of non-PLWH were prescribed ≥ 5 medications, only increasing to 32% in 2010. Older age (30-49 y and ≥ 50 y) was associated with ≥ 5 prescription medications in PLWH (adjusted odds ratio [aOR] = 2.538, 95% CI; 1.31-4.918 and aOR = 2.703, 95% CI; 1.678-4.354) and in non-PLWH (aOR = 2.546, 95% CI; 2.235-2.9 and aOR = 5.208, 95% CI; 4.486-6.047), respectively. Prescription of multiple medications is on the rise in PLWH, more so than in non-PLWH. Additional research is needed to explore how prescription of multiple medications differentially affects younger PLWH vs. older PLWH.

Entities:  

Keywords:  HIV; antiretroviral therapy; comorbidities; older adults; polypharmacy

Mesh:

Year:  2015        PMID: 26608408     DOI: 10.1080/09540121.2015.1109583

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  16 in total

1.  Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence.

Authors:  Theresa W Kim; Alexander Y Walley; Timothy C Heeren; Gregory J Patts; Alicia S Ventura; Gabriel B Lerner; Nicholas Mauricio; Richard Saitz
Journal:  J Subst Abuse Treat       Date:  2017-07-14

Review 2.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

3.  Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis.

Authors:  Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash
Journal:  AIDS Patient Care STDS       Date:  2019-03       Impact factor: 5.078

4.  Risk of Complications After THA Increases Among Patients Who Are Coinfected With HIV and Hepatitis C.

Authors:  Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

5.  Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence.

Authors:  Theresa W Kim; Alexander Y Walley; Alicia S Ventura; Gregory J Patts; Timothy C Heeren; Gabriel B Lerner; Nicholas Mauricio; Richard Saitz
Journal:  AIDS Care       Date:  2017-10-16

6.  Geriatric conditions and healthcare utilisation in older adults living with HIV.

Authors:  Meredith Greene; Ying Shi; John Boscardin; Rebecca Sudore; Monica Gandhi; Kenneth Covinsky
Journal:  Age Ageing       Date:  2022-05-01       Impact factor: 12.782

7.  Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study.

Authors:  Kendra K Radtke; Peter Bacchetti; Kathryn Anastos; Daniel Merenstein; Howard Crystal; Roksana Karim; Kathleen M Weber; Andrew Edmonds; Anandi N Sheth; Margaret A Fischl; David Vance; Ruth M Greenblatt; Leah H Rubin
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

Review 8.  Deprescribing of non-antiretroviral therapy in HIV-infected patients.

Authors:  José-Ramón Blanco; Ramón Morillo; Vicente Abril; Ismael Escobar; Enrique Bernal; Carlos Folguera; Fátima Brañas; Mercedes Gimeno; Olatz Ibarra; José-Antonio Iribarren; Alicia Lázaro; Ana Mariño; María-Teresa Martín; Esteban Martinez; Luis Ortega; Julian Olalla; Aguas Robustillo; Matilde Sanchez-Conde; Miguel-Angel Rodriguez; Javier de la Torre; Javier Sanchez-Rubio; Montse Tuset
Journal:  Eur J Clin Pharmacol       Date:  2019-12-21       Impact factor: 2.953

9.  Examination of Polypharmacy Trajectories Among HIV-Positive and HIV-Negative Men in an Ongoing Longitudinal Cohort from 2004 to 2016.

Authors:  Deanna Ware; Frank J Palella; Kara W Chew; M Reuel Friedman; Gypsyamber D'Souza; Ken Ho; Michael Plankey
Journal:  AIDS Patient Care STDS       Date:  2019-08       Impact factor: 5.944

10.  Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.

Authors:  Krista J Siefried; Limin Mao; Lucette A Cysique; John Rule; Michelle L Giles; Don E Smith; James McMahon; Tim R Read; Catriona Ooi; Ban K Tee; Mark Bloch; John de Wit; Andrew Carr
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.